Is there a difference between GBS triggered by COVID-19 and those of other origins?

Radišić, Vanja; Ždraljević, Mirjana; Perić, Stojan; Mladenovic, Branka; Ralić, Branislav; Jovanović, Dejana; Berisavac, Ivana

doi:10.1186/s41983-022-00486-6

Cited by 4 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two patients (0.8%) showed normal electrophysiology. In six cohorts the summed percentage of patients with AIDP was 60.8% in SARS‐CoV‐2 infected patients and 51.8% in non‐infected patients with a non‐significant difference (RR 1.13, 95% CI 0.87; 1.47) (Figure 7a) [9, 28, 45–48]. Axonal GBS (AMAN and AMSAN) was 21.7% in SARS‐CoV‐2 infected and 25.7% in non‐infected patients with a 0.24 times lower risk of axonal GBS in SARS‐CoV‐2 infected patients (RR 0.76, 95% CI 0.56; 1.12) (Figure 7b).…”

Section: Resultsmentioning

confidence: 99%

“…In four cohorts the raw percentage of cranial nerve involvement was 37.5% in non‐SARS‐CoV‐2 infected patients and 49.1% in SARS‐CoV‐2 infected patients with 1.41 RR of cranial nerve involvement (RR 1.41, 95% CI 1.09; 1.83) (Figure 6c) [9, 28, 45, 46].…”

Section: Resultsmentioning

confidence: 99%

“…In five cohort studies the summed percentage of deceased patients was 1.28% in SARS‐CoV‐2 infected patients and 5.05% in non‐infected patients (Figure 6d) [9, 27, 45, 46, 48]. A 0.31 times reduced risk of death was found in the SARS‐CoV‐2 infected GBS population (RR 0.69, 95% CI 0.12; 3.87).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Guillain−Barré syndrome and SARS‐CoV‐2 infection: a systematic review and meta‐analysis on a debated issue and evidence for the ‘Italian factor’

Censi,

Bisaccia,

Gallina

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeThe association between Guillain−Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is debated. This study reappraises, after three pandemic years, the epidemiological data and the features of GBS in SARS‐CoV‐2 patients.MethodsA systematic review and meta‐analysis of case reports/series and cohort studies published between 1 January 2020 and 19 April 2023 was performed.ResultsIn all, 209 case reports/series (304 patients) and 26 cohort studies were included. The risk of GBS in northern Italy during the first pandemic wave was 2.85 times increased (95% confidence interval [CI] 1.54; 5.25) whereas in some countries the risk during the first pandemic year was 0.17 times reduced (risk ratio 0.83, 95% CI 0.75; 0.93). The incidence of GBS in SARS‐CoV‐2 Italian hospitalized cohorts was 8.55 per 1000 (95% CI 5.33; 12.49) with an estimated incidence of 0.13 GBS per 1000 in the SARS‐CoV‐2 infected population. In European cohorts the pooled rate of GBS with SARS‐CoV‐2 infection was 61.3% of the total. GBS patients with SARS‐CoV‐2 infection showed more frequently, but not differently from non‐infected patients, the classical clinical presentation and the demyelinating subtype. Cranial nerves were more frequently involved in SARS‐CoV‐2 infected patients.ConclusionsAn increased risk of GBS occurred in northern Italy during early COVID‐19 pandemic. The recognition of the ‘Italian factor’ reconciles contrasting results of the epidemiological studies. The slightly reduced GBS risk in other countries and the relatively high frequency of GBS associated with SARS‐CoV‐2 infection can be explained by the adopted health measures that decreased the circulation of other GBS infective antecedents.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Guillain−Barré syndrome and SARS‐CoV‐2 infection: a systematic review and meta‐analysis on a debated issue and evidence for the ‘Italian factor’

Censi,

Bisaccia,

Gallina

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…In the case of our female patient, the first symptoms started 15 days after infection. Radišić et al [ 10 ] showed that there was no difference in clinical and electrophysiological features, disease course, and outcome between post-COVID-19 and non-COVID-19 GBS patients. As for rehabilitation outcomes of post-COVID-19 GBS patients, there are limited data.…”

Section: Discussionmentioning

confidence: 99%

Rehabilitation of Rare Neurological Complications of COVID-19 Infection in Health Resort Settings

Kurtanović,

Gogić,

Tanović

et al. 2024

Cureus

View full text Add to dashboard Cite

There is increasing evidence of neurological involvement in patients with coronavirus disease. Reports of neurological manifestations include altered mental status, Guillain-Barré syndrome (GBS) and its forms, encephalopathy, psychosis, neurocognitive (dementia) syndrome, ischemic strokes, intracerebral hemorrhage, and acute transverse myelitis. We present three patients with rare neurological manifestations of the COVID-19 disease, with a special focus on rehabilitation in a health resort setting. Outcomes were evaluated based on neurological examination and the modified Barthel index. We highlight the importance of an interdisciplinary approach to reduce disability and improve functionality and quality of life.

show abstract

“…Although the experiences of some studies indicate that post-COVID-19, GBS is a more severe in comparison with other post-infective GBS,[ 16 ] our study has not confirmed that. [ 17 ]…”

Section: Discussionmentioning

confidence: 99%

Guillain-Barre Syndrome Followed by Covid-19 Infection, Vaccination and Other Precipitating Factors during the Pandemic

Martic,

Fejzic,

Danilovic

et al. 2023

Annals of Indian Academy of Neurology

View full text Add to dashboard Cite

Background and Aims: Guillain-Barré syndrome (GBS) is usually triggered by an infection. Vaccination is mentioned as a possible trigger in a small number of GBS cases. The aim of this study was to notice GBS distinctness provoked by various triggers during the COVID-19 pandemic. Material and Methods: A total of 109 GBS patients were divided into three groups, respectively: COVID-19 infection associated (19 patients), COVID-19 vaccination associated (16 patients) and precipitated by some other factors (74 patients). We compared the clinical, neurophysiological and laboratory characteristics of these three groups. Results: Neither were differences recorded in the age of the patients of these three groups at the time of illness, nor in the number of days from the precipitating factor to the onset of symptoms. There were no clinical differences between groups related to severity of the disease or patients’ recovery. The only clinical difference was observed in relation to facial nerve bilateral affection because it was significantly higher in the post-vaccination group. According to neurophysiological findings, demyelinating form dominated in all three groups. Conclusion: Clinical characteristics, electrophysiological findings and laboratory characteristics did not differ significantly in Guillain-Barre syndrome followed by COVID-19 infection, vaccination and other precipitating factors during the pandemic. The bilateral involvement of facial nerves was significantly higher in the post-vaccination group. Most of these cases had a mild form of the disorder—distal paresthesias GBS variant.

show abstract

Is there a difference between GBS triggered by COVID-19 and those of other origins?

Cited by 4 publications

References 36 publications

Guillain−Barré syndrome and SARS‐CoV‐2 infection: a systematic review and meta‐analysis on a debated issue and evidence for the ‘Italian factor’

Guillain−Barré syndrome and SARS‐CoV‐2 infection: a systematic review and meta‐analysis on a debated issue and evidence for the ‘Italian factor’

Rehabilitation of Rare Neurological Complications of COVID-19 Infection in Health Resort Settings

Guillain-Barre Syndrome Followed by Covid-19 Infection, Vaccination and Other Precipitating Factors during the Pandemic

Contact Info

Product

Resources

About